Zhaoke Pharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zhaoke Pharmaceutical Limited
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
- Other Names / Subsidiaries
- Zhaoke Pharmaceutical (Guangzhou) Co. Ltd.
- Zhaoke GZ
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.